Encyclopedia

  • Short-term hemodynamic, anti-ischemic, and antianginal effects of Pirsidomine (cas 132722-74-8), a now sydnonimine☆
  • Add time:08/25/2019         Source:sciencedirect.com

    Pirsidomine is a new sydnonimine compound in clinical development. As a prodrug, it is transformed into a nitric oxide-releasing metabolite in vivo. In animal tests there were no signs of tolerance with repeated administration. The short-term effects of 10, 20, and 40 mg of the drug on pulmonary hemodynamics and ischemic parameters were examined at rest and during exercise in a double-blind, randomized, placebo-controlled study. The study included 48 patients with documented coronary artery disease and exercise-induced ST-segment depression. Compared with the baseline test, there was a reduction of diastolic pulmonary artery pressure with pirsidomine at rest (placebo: −0.4 ± 0.5 mm Hg; 10 mg: −1.5 ± 2.4 mm Hg; 20 mg: −1.4 ± 1.1 mm Hg; 40 mg: −2.3 ±1.3 mm Hg [p < 0.05]) and at the highest comparable workload (placebo: −2.8 ± 1.9 mm Hg; 10 mg: −7.3 ± 6.8 mm Hg; 20 mg: −8.4 ± 7.9 mm Hg [p < 0.05]; 40 mg: −13.8 ± 7.1 mm Hg [p < 0.05]). ST-segment depression decreased at the highest comparable workload (placebo: −0.33 ± 0.49 mm; 10 mg: −1.33 ± 1.37 mm [p < 0.05]; 20 mg: −1.33 ± 0.83 mm [p < 0.05]; 40 mg: −1.96 ± 0.86 mm [p < 0.05]) and total exercise time increased (placebo: 15 ± 48 s; 10 mg: 98 ± 126 s; 20 mg: 165 ± 251 s [p < 0.05]; 40 mg: 155 ± 174 s [p < 0.05]). Of 40 patients who complained of angina pectoris symptoms in the base-line test, 15 became free of angina pectoris with pirsidomine. Compared with placebo, blood pressure, heart rate during exercise, and cardiac output during exercise showed no significant change. Plasma concentration response relations of the metabolite revealed concentrations that caused a half-maximum effect of 6 ng/ml, 13 ng/ml, 20 ng/ml, and 28 ng/ ml in reduction of ST-segment depression, reduction of diastolic pulmonary artery pressure, relief of angina pectoris symptoms, and an increase in exercise duration, respectively. Thus, pirsidomine is an effective anti-ischemic and antianginal agent. A significant preload reduction was obtained with plasma metabolite concentrations lower than those necessary to achieve a satisfactory antianginal effect.

    We also recommend Trading Suppliers and Manufacturers of Pirsidomine (cas 132722-74-8). Pls Click Website Link as below: cas 132722-74-8 suppliers


    Prev:Cardiovascular effects of the new nitric oxide donor, Pirsidomine (cas 132722-74-8). Hemodynamic profile and tolerance studies in anesthetized and conscious dogs
    Next: A potentially simple 13C NMR method to assign regio- and stereochemistry of (2′-deoxy-2′-fluoroarabinofuranosyl) nucleosides.)

About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia

Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog

©2008 LookChem.com,License: ICP

NO.:Zhejiang16009103

complaints:service@lookchem.com Desktop View